Association between infectious event and de novo malignancy after heart transplantation

被引:0
|
作者
Chie Bujo
Eisuke Amiya
Masaru Hatano
Masaki Tsuji
Hisataka Maki
Junichi Ishida
Satoshi Ishii
Koichi Narita
Miyoko Endo
Masahiko Ando
Shogo Shimada
Osamu Kinoshita
Minoru Ono
Issei Komuro
机构
[1] The University of Tokyo,Department of Cardiovascular Medicine, Graduate School of Medicine
[2] The University of Tokyo,Department of Therapeutic Strategy for Heart Failure
[3] The University of Tokyo,Department of Cardiac Surgery, Graduate School of Medicine
[4] The University of Tokyo,Departmant of Nursing, Graduate School of Medicine
来源
Heart and Vessels | 2021年 / 36卷
关键词
Heart transplantation; Malignancy; Posttransplant lymphoproliferative disorder;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the study was to investigate the incidence of and risk factors for de novo malignancy after heart transplantation (HTx) in a single center. We assessed 102 consecutive patients who received HTx and were followed-up in our center regularly for > 1 year from June 2006 to May 2018. We investigated the incidence of and risk factors for de novo malignancy. The cumulative incidence of each malignancy type during the follow-up period was one (0.98%) for skin cancer, four (3.92%) for nonskin solid organ cancer, and six (5.88%) for posttransplant lymphoproliferative disorder (PTLD). The percentage of patients with more than one infectious event ≤ 1 year after HTx was higher in the malignancy group than in the non-malignancy group. Furthermore, Kaplan–Meier analysis revealed that the incidence rate of infectious events was higher in patients with malignancies than in those without (log-rank P < 0.001). After dividing malignancies into a PTLD group and a solid organ malignancy group, we found that negative Epstein–Barr virus serostatus, cytomegalovirus-positive antigenemia, and the occurrence of any viral or gastrointestinal infectious event at ≤ 1 year were more frequent in patients with PTLD than in patients without it. The survival rate was significantly lower for patients with solid organ malignancy than for patients without malignancy. In conclusion, there was a correlation between infectious events and de novo malignancy, particularly in patients with PTLD. We should confirm this finding by conducting a larger cohort study.
引用
收藏
页码:499 / 508
页数:9
相关论文
共 50 条
  • [21] De Novo Malignancy after Liver Transplantation for Alcoholic Cirrhosis: Incidence and Outcomes
    Pascale, M. M.
    Nure, E.
    Bianco, G.
    Frongillo, F.
    Agnes, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 836 - 836
  • [22] De Novo Pulmonary Arterial Hypertension After Heart Transplantation
    Ahsan, Syed A.
    Berger, Joseph I.
    Lanier, Gregg
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S107 - S107
  • [23] High rates of de novo malignancy compromise post-heart transplantation survival
    Giuliano, Katherine
    Canner, Joseph K.
    Etchill, Eric
    Suarez-Pierre, Alejandro
    Choi, Chun W.
    Higgins, Robert S. D.
    Hsu, Steven
    Sharma, Kavita
    Kilic, Ahmet
    JOURNAL OF CARDIAC SURGERY, 2021, 36 (04) : 1401 - 1410
  • [24] Characterization of de novo malignancy after orthotopic heart transplantation: single-centre outcomes over 20 years
    Bakir, Nadia H.
    Florea, Ioana B.
    Phillipps, Jordan
    Schilling, Joel D.
    Damiano, Marci S.
    Ewald, Gregory A.
    Itoh, Akinobu
    Kotkar, Kunal D.
    Damiano Jr, Ralph J.
    Moon, Marc R.
    Masood, Muhammad F.
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2023, 64 (04)
  • [25] Malignancy After Heart Transplantation
    Chen, Po-Lin
    Chang, Hsiao-Huang
    Chen, I-Ming
    Lai, Shiau-Ting
    Shih, Chun-Che
    Weng, Zen-Chung
    Hsieh, Yuan-Chen
    Yang, An-Hang
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2009, 72 (11) : 588 - 593
  • [26] De Novo Malignancy Following Liver Transplantation.
    Kazemi, Kourosh
    Sanaei, Ahmad Kh
    Aliakbarian, Mohsen
    Malek-Hosseini, Seyed Ali
    LIVER TRANSPLANTATION, 2013, 19 : S278 - S278
  • [27] Management of De novo Malignancy Following Liver Transplantation
    Currier, Emily E.
    Sadiq, Omar
    Jafri, Syed-Mohammed
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : 1285 - 1285
  • [28] De Novo Malignancy After Liver Transplant
    Sanaei, Ahmad Khalid
    Aliakbarian, Mohsen
    Kazemi, Kourosh
    Nikeghbalian, Saman
    Shamsaeefar, Ali
    Mehdi, Syed Haider
    Bahreini, Amin
    Dehghani, Seyed Mohsen
    Geramizadeh, Bita
    Malekhosseini, Seyed Ali
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2015, 13 (02) : 163 - 166
  • [29] The janus face of immunosuppression -: de novo malignancy after renal transplantation:: the experience of the Transplantation Center Munich
    Wimmer, C. D.
    Rentsch, M.
    Crispin, A.
    Illner, W. D.
    Arbogast, H.
    Graeb, C.
    Jauch, K-W
    Guba, M.
    KIDNEY INTERNATIONAL, 2007, 71 (12) : 1271 - 1278
  • [30] MINIMIZATION OF IMMUNOSUPPRESSION AFTER LIVER TRANSPLANTATION FROM THE PERSPECTIVES OF 'DE NOVO MALIGNANCY' AND 'NEPHROTOXICITY'
    Kim, In-Gyu
    Hu, Xu-Guang
    Wang, Hee-Jung
    Kim, Bong-Wan
    Hong, Sung Yeon
    TRANSPLANT INTERNATIONAL, 2017, 30 : 479 - 479